GlassScriptPhysician profile
Nuri J Jacoby
NPI 1275769747
$13,627.55
in general payments reported to CMS, 2019-2025
28 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $2,249 · 2021: $233 · 2022: $1,561 · 2023: $2,055 · 2024: $6,608 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,795 · Food and Beverage: $1,302 · Travel and Lodging: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,794.63 |
| Food and Beverage | $1,302.27 |
| Travel and Lodging | $115.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,338.89 | 2024 | Uplizna |
| Argenx US, INC. | $3,624.48 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $2,335.50 | 2020-2025 | Ultomiris |
| Sk Life Science, INC. | $241.70 | 2023-2025 | |
| Grifols USA, LLC | $105.11 | 2019-2025 | Gamunex-C |
| Ucb, INC. | $94.55 | 2019-2024 | Briviact, Rystiggo |
| Astrazeneca Pharmaceuticals LP | $91.01 | 2024-2025 | |
| Csl Behring | $82.17 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $79.66 | 2019 | |
| Immedica Pharma US, INC. | $51.38 | 2023-2024 | |
| Allergan, INC. | $50.60 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $49.80 | 2019 | |
| Abbvie INC. | $46.41 | 2025 | |
| Alnylam Pharmaceuticals INC. | $45.59 | 2023-2025 | Amvuttra |
| Genentech USA, INC. | $40.90 | 2022-2023 | Evrysdi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $39.83 | 2020 | |
| Biogen, INC. | $39.01 | 2025 | Vumerity, Leqembi |
| Merz North America, INC. | $33.62 | 2020 | |
| Akcea Therapeutics, INC. | $32.91 | 2019 | |
| Aucta Pharmaceuticals, INC. | $30.97 | 2025 | Motpoly Xr |
| Eisai INC. | $30.64 | 2024 | |
| Medtronic USA, INC. | $24.79 | 2019 | |
| Genzyme Corporation | $22.94 | 2019 | |
| Neurelis, INC. | $22.89 | 2024 | Valtoco |
| Pfizer INC. | $21.56 | 2025 | |
| Emd Serono, INC. | $18.44 | 2019 | |
| Acorda Therapeutics, INC | $17.50 | 2019 | |
| Cardiva Medical, INC. | $14.70 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuri Jacoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.